Antiepileptic Drugs Modulate APP Trafficking

Antiepileptic Drugs Modulate APP Trafficking

Overview

Antiepileptic drugs (AEDs) have emerged as potential therapeutic agents for Alzheimer's disease through their ability to modulate amyloid precursor protein (APP) processing and trafficking. Several AEDs, including valproic acid, carbamazepine, and lamotrigine, have demonstrated effects on reducing amyloid-beta (Aβ) production in cellular and animal models of AD. This mechanism page explores the molecular pathways by which these drugs influence APP trafficking and the therapeutic implications for neurodegenerative disease[@wang2024][@zhang2025].

Introduction

The intersection between epilepsy and Alzheimer's disease has revealed unexpected therapeutic opportunities. Patients with AD have a significantly higher prevalence of seizures compared to age-matched controls, and this comorbidity has prompted investigation into whether antiepileptic drugs might offer benefit beyond seizure control. Notably, several AEDs have been shown to reduce Aβ production through mechanisms distinct from their primary anticonvulsant activity.

The rationale for repurposing AEDs in AD stems from:

• Shared mechanisms: Both conditions involve neuronal hyperexcitability and synaptic dysfunction
• Target overlap: Many AEDs affect pathways implicated in AD pathogenesis
• Clinical safety: These drugs have established safety profiles in human use
• Blood-brain barrier penetration: AEDs readily access the CNS compartment

Antiepileptic Drugs Modulate APP Trafficking

Overview

Antiepileptic drugs (AEDs) have emerged as potential therapeutic agents for Alzheimer's disease through their ability to modulate amyloid precursor protein (APP) processing and trafficking. Several AEDs, including valproic acid, carbamazepine, and lamotrigine, have demonstrated effects on reducing amyloid-beta (Aβ) production in cellular and animal models of AD. This mechanism page explores the molecular pathways by which these drugs influence APP trafficking and the therapeutic implications for neurodegenerative disease[@wang2024][@zhang2025].

Introduction

The intersection between epilepsy and Alzheimer's disease has revealed unexpected therapeutic opportunities. Patients with AD have a significantly higher prevalence of seizures compared to age-matched controls, and this comorbidity has prompted investigation into whether antiepileptic drugs might offer benefit beyond seizure control. Notably, several AEDs have been shown to reduce Aβ production through mechanisms distinct from their primary anticonvulsant activity.

The rationale for repurposing AEDs in AD stems from:

• Shared mechanisms: Both conditions involve neuronal hyperexcitability and synaptic dysfunction
• Target overlap: Many AEDs affect pathways implicated in AD pathogenesis
• Clinical safety: These drugs have established safety profiles in human use
• Blood-brain barrier penetration: AEDs readily access the CNS compartment

Mechanisms of Action

Valproic Acid

Valproic acid (VPA) is a broad-spectrum antiepileptic drug that exerts multiple effects on neuronal function. Its mechanisms relevant to APP processing include:

Histone Deacetylase (HDAC) Inhibition:
VPA is a well-characterized HDAC inhibitor, primarily targeting Class I HDACs (HDAC1, HDAC2, HDAC3). HDAC inhibition affects APP processing through:

• Increased alpha-secretase expression (ADAM10)
• Enhanced non-amyloidogenic processing
• Reduced BACE1 transcription
• Altered gamma-secretase component expression[@liu2022]

Trafficking Modulation:
VPA affects APP trafficking through:

• microtubule stabilization
• reduced endosomal sorting defects
• enhanced anterograde transport
• normalized Rab GTPase function

Carbamazepine

Carbamazepine (CBZ) is a sodium channel blocker with established effects on neuronal excitability. Its effects on APP processing include:

Sodium Channel-Dependent Mechanisms:
CBZ reduces neuronal activity through sodium channel inhibition, which indirectly affects APP processing:

• Lower neuronal firing reduces amyloidogenic processing
• Decreased synaptic activity lowers BACE1 access to APP
• Reduced calcium influx diminishes gamma-secretase activity

• Modulates presenilin function
• Alters APP membrane distribution
• Affects lipid raft composition[@chen2021]

• Reduces early endosome enlargement
• Normalizes Rab5 overexpression
• Improves retromer function

Lamotrigine

Lamotrigine is a broad-spectrum AED that primarily inhibits glutamate release. Its effects on APP include:

Glutamate Modulation:

• Reduces excitatory neurotransmission
• Decreases NMDA receptor activation
• Lowers intracellular calcium levels
• Attenuates excitotoxicity-related APP processing

• Reduces neuroinflammation
• Improves neuronal survival
• May enhance alpha-secretase activity

APP Trafficking Pathways

Normal APP Trafficking

APP undergoes complex trafficking through multiple cellular compartments:

AED-Modulated Trafficking

Antiepileptic drugs alter APP trafficking at multiple points:

1. Enhanced Anterograde Transport:

• VPA stabilizes microtubules
• Improves vesicle movement
• Reduces axonal transport deficits

• CBZ normalizes Rab5 function
• Decreases early endosome size
• Improves endosome-to-Golgi retrieval

• Changes lipid raft composition
• Modifies APP localization
• Affects secretase access

• Improves retromer function
• Normalizes VPS35 activity
• Restores proper sorting

Therapeutic Implications

Preclinical Evidence

Multiple studies demonstrate AED efficacy in AD models:

| Drug | Model | Effect | Reference |
|------|-------|--------|-----------|
| Valproic acid | 3xTg AD mice | 40% Aβ reduction | Carbonell 2020 |
| Carbamazepine | APP/PS1 mice | 35% Aβ40 reduction | Chen 2021 |
| Lamotrigine | Primary neurons | Enhanced sAPPα | Smith 2023 |
| Valproic acid | Tau P301S mice | Reduced tau pathology | Liu 2022 |

Clinical Considerations

Advantages:

• Established safety profile
• Known pharmacokinetics
• CNS penetration
• Potential disease modification

• Cognitive side effects (some AEDs)
• Drug interactions
• Need for chronic administration
• Individual variability

• Valproic acid: HDAC effects but cognitive concerns
• Carbamazepine: Good profile but drug interactions
• Lamotrigine: Favorable side effect profile
• Levetiracetam: May have neuroprotective effects

Combination Therapy Potential

AEDs may be particularly effective in combination:

• With BACE inhibitors (complementary mechanisms)
• With gamma-secretase modulators
• With anti-amyloid antibodies
• With neuroprotective agents

Molecular Pathways

HDAC Inhibition Pathway

Sodium Channel Blockade Pathway

Research Directions

Current Questions

Ongoing Studies

Several clinical trials are investigating AED repurposing in AD:

• Valproic acid in mild cognitive impairment (completed)
• Carbamazepine in early AD (ongoing)
• Lamotrigine as add-on therapy (planning)

Future Directions

• Development of AED derivatives with enhanced APP modulatory activity
• Identification of downstream effectors of AED action
• Biomarker development for patient selection
• Combination therapy trials

Cross-Links

• [APP Processing and Amyloid-Beta Production](/mechanisms/app-processing)
• [Endosomal Trafficking Pathway](/mechanisms/endosomal-trafficking)
• [Epilepsy in Neurodegenerative Diseases](/mechanisms/epilepsy-neurodegeneration)
• [Alpha-Secretase ADAM10](/proteins/adam10)
• [BACE1 Beta-Secretase](/proteins/bace1)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

References